Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem's products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
Company profile
Ticker
ENZ
Exchange
Website
CEO
Elazar Rabbani
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Enzo Clinical Labs, Inc. • Enzo Life Sciences, Inc. • Enzo Therapeutics, Inc. • Enzo Realty LLC • Enzo Realty II, LLC ...
IRS number
132866202
ENZ stock data
Latest filings (excl ownership)
10-Q
2023 Q2
Quarterly report
20 Mar 23
DEFA14A
Additional proxy soliciting materials
16 Mar 23
8-K
Enzo Biochem Agrees to Sell Clinical Laboratory to Labcorp
16 Mar 23
NT 10-Q
Notice of late quarterly filing
14 Mar 23
8-K
Submission of Matters to a Vote of Security Holders
3 Feb 23
DEFR14A
Revised proxy
20 Dec 22
DEF 14A
Definitive proxy
20 Dec 22
10-Q
2023 Q1
Quarterly report
12 Dec 22
10-K/A
2022 FY
Annual report (amended)
25 Nov 22
8-K
Departure of Directors or Certain Officers
3 Nov 22
Transcripts
ENZ
Earnings call transcript
2023 Q1
13 Dec 22
ENZ
Earnings call transcript
2022 Q3
10 Jun 22
ENZ
Earnings call transcript
2022 Q2
15 Mar 22
ENZ
Earnings call transcript
2022 Q1
16 Dec 21
ENZ
Earnings call transcript
2021 Q4
12 Oct 21
ENZ
Earnings call transcript
2021 Q3
10 Jun 21
ENZ
Earnings call transcript
2021 Q2
16 Mar 21
ENZ
Earnings call transcript
2021 Q1
10 Dec 20
ENZ
Earnings call transcript
2020 Q4
13 Oct 20
ENZ
Earnings call transcript
2020 Q3
8 Jun 20
Latest ownership filings
SC 13D
LABORATORY CORP OF AMERICA HOLDINGS
27 Mar 23
4
James G. Wolf
13 Feb 23
4
Ian B. Walters
13 Feb 23
4
MARY TAGLIAFERRI
13 Feb 23
4
Bradley Louis Radoff
13 Feb 23
SC 13G/A
RENAISSANCE TECHNOLOGIES LLC
13 Feb 23
4
Kara Cannon
31 Jan 23
4
James G. Wolf
30 Jan 23
SC 13D/A
Wolf James G.
23 Jan 23
4
James G. Wolf
23 Jan 23
Financial summary
| Quarter (USD) | Jan 23 | Oct 22 | Jul 22 | Apr 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Jul 22 | Jul 21 | Jul 20 | Jul 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 6.05 mm | 6.05 mm | 6.05 mm | 6.05 mm | 6.05 mm | 6.05 mm |
| Cash burn (monthly) | 2.36 mm | (no burn) | 4.33 mm | 3.08 mm | 2.07 mm | 2.07 mm |
| Cash used (since last report) | 4.76 mm | n/a | 8.73 mm | 6.21 mm | 4.17 mm | 4.17 mm |
| Cash remaining | 1.29 mm | n/a | -2.68 mm | -152.65 k | 1.88 mm | 1.88 mm |
| Runway (months of cash) | 0.5 | n/a | -0.6 | -0.0 | 0.9 | 0.9 |
Institutional ownership, Q4 2022
49.0% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 53 |
| Opened positions | 7 |
| Closed positions | 5 |
| Increased positions | 10 |
| Reduced positions | 12 |
| 13F shares | Current |
|---|---|
| Total value | 17.48 bn |
| Total shares | 24.31 mm |
| Total puts | 82.50 k |
| Total calls | 25.60 k |
| Total put/call ratio | 3.2 |
| Largest owners | Shares | Value |
|---|---|---|
| Harbert Fund Advisors | 5.18 mm | $7.40 bn |
| Harbert Discovery Fund | 5.18 mm | $17.03 mm |
| Renaissance Technologies | 2.81 mm | $4.02 mm |
| Roumell Asset Management | 2.13 mm | $3.04 bn |
| Vanguard | 1.77 mm | $2.53 bn |
| Dimensional Fund Advisors | 1.61 mm | $2.31 mm |
| BLK Blackrock | 1.43 mm | $2.04 bn |
| Fuller & Thaler Asset Management | 983.29 k | $1.41 mm |
| Potomac Capital Management | 569.00 k | $814.00 k |
| Radoff Bradley Louis | 400.00 k | $1.25 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 13 Feb 23 | Wolf James G. | Common Stock, $0.01 par value | Buy | Acquire P | Yes | No | 1.29 | 5,000 | 6.45 k | 115,000 |
| 13 Feb 23 | Wolf James G. | Common Stock, $0.01 par value | Buy | Acquire P | No | No | 1.285 | 5,000 | 6.43 k | 4,100,000 |
| 13 Feb 23 | Wolf James G. | Short Put Option (obligation to buy) Common Stock, $0.01 par value | Sell | Acquire S | No | No | 1.12 | 750 | 840.00 | 2,163 |
| 13 Feb 23 | Wolf James G. | Short Put Option (obligation to buy) Common Stock, $0.01 par value | Sell | Dispose S | No | No | 0.03 | 750 | 22.50 | 0 |
| 13 Feb 23 | Wolf James G. | Short Put Option (obligation to buy) Common Stock, $0.01 par value | Sell | Acquire S | No | No | 1.01 | 324 | 327.24 | 324 |
| 13 Feb 23 | Wolf James G. | Long Call Option Common Stock, $0.01 par value | Sell | Dispose S | No | No | 0.19 | 324 | 61.56 | 483 |
| 13 Feb 23 | Ian B. Walters | Common Stock, $0.01 Par Value | Grant | Acquire A | No | No | 0 | 75,188 | 0.00 | 155,917 |
| 10 Feb 23 | Wolf James G. | Common Stock, $0.01 par value | Buy | Acquire P | No | No | 1.29 | 5,000 | 6.45 k | 4,095,000 |
| 9 Feb 23 | Radoff Bradley Louis | Common Stock, $0.01 Par Value | Grant | Acquire A | No | No | 0 | 75,188 | 0.00 | 4,311,517 |
| 9 Feb 23 | Mary Tagliaferri | Common Stock, $0.01 Par Value | Grant | Acquire A | No | No | 0 | 75,188 | 0.00 | 155,917 |
News
Enzo Biochem Q2 Sales $16.30M Down From $34.05M YoY
21 Mar 23
12 Health Care Stocks Moving In Friday's Intraday Session
17 Mar 23
Why Baidu Shares Are Trading Higher By More Than 6%? Here Are Other Stocks Moving In Friday's Mid-Day Session
17 Mar 23
Crude Oil Down 2%; Enzo Biochem Shares Spike Higher
17 Mar 23
What In The World Is Going On With Enzo Biochem (ENZ) Stock?
17 Mar 23